The Leukemia & Lymphoma Society & Walgreens Partner To Support Cancer Patients In Their Communities
RYE BROOK, N.Y. and DEERFIELD, Ill., March 16, 2016 /PRNewswire-USNewswire/ — The Leukemia & Lymphoma Society (LLS) and Walgreen Co. today announced the launch of an innovative collaboration designed to further advance cancer therapies and address the changing treatment model facing patients with blood and other cancers. The collaboration, between LLS and Walgreens Specialty Pharmacy, builds on the heritage of Walgreens in serving its communities, and the 66-year history of LLS, which has invested more than $1 billion in research to advance blood cancer treatments and cures.
“We are proud to team up with LLS on this transformational approach to empowering and supporting patients through our expert oncology specialized pharmacies across the country,” said Richard Ashworth, president, pharmacy and retail operations for Walgreens. “With our aligned missions and commitment to serving patients and families, LLS and Walgreens will make an even greater impact on the health and care of the nearly 1.2 million people in the U.S. living with or in remission from a blood cancer.”
As new blood cancer therapies come to market and patients are able to manage their disease with oral medications at home, specialized pharmacists are well-positioned on the front lines of patient care to help facilitate this treatment transition and play a significant role in providing access to these new therapies.
This collaboration will help patients, families and caregivers in three key ways: